We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Microarray-Based Glycoprofiling Test Diagnoses Ovarian Cancer

By LabMedica International staff writers
Posted on 27 Mar 2014
Cancer researchers have developed a microarray assay that identifies the abnormally glycosylated surface residues associated with ovarian tumor biomarker proteins such as CA125.

The CA125 biomarker assay plays an important role in the diagnosis and management of invasive ovarian cancer. More...
However, a fundamental problem with CA125 is that it is not cancer-specific and may be elevated in benign gynecological conditions such as benign ovarian neoplasms and endometriosis.

Investigators at the University of Copenhagen (Denmark) based the development of a new assay system for glycoprofiling ovarian cancer on the observation that aberrant O-glycosylation was an inherent and specific property of cancer cells and could aid in differentiating cancer from these benign conditions, thereby improving specificity of the assay.

They developed a novel microarray-based platform for profiling specific aberrant glycoforms, such as Neu5Acalpha2,6GalNAc (STn) and GalNAc (Tn), present on CA125 and CA15-3. They used the assay to measure STn-CA125, ST-CA125, and STn-CA15-3 in a blinded study of a cohort of patients from the United Kingdom Ovarian Cancer Population Study who presented with elevated CA125 levels and a pelvic mass.

Results revealed that the combined glycoform profile was able to distinguish benign ovarian neoplasms from invasive epithelial ovarian cancer with a specificity of 61.1% at 90% sensitivity.

“All proteins have a type of sugar-coat – small, complicated sugar molecules that reside on a protein’s surface. When cancer is present in the body, we can observe a chemical change in this sugar-coat. It is a very complex phenomenon. Luckily, it is very simple to investigate and determine the presence of this transformed sugar coating,” said senior author Dr. Ola Blixt, professor of chemistry at the University of Copenhagen. “We have decided to publish these results, as opposed to taking out a patent. OK, we will not get rich, even though the market related to ovarian cancer is worth 170 million USD annually. On the other hand, any manufacturer is able to include this in their existing kit. And I hope that it happens soon.”

The study describing the ovarian cancer glycoprofiling assay was published in the January 29, 2014, online edition of the Journal of Proteome Research.

Related Links:

University of Copenhagen



New
Gold Member
Hematology Analyzer
Medonic M32B
Collection and Transport System
PurSafe Plus®
Specimen Radiography System
TrueView 200 Pro
New
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Over 100 new epigenetic biomarkers may help predict cardiovascular disease risk (Photo courtesy of 123RF)

Routine Blood Draws Could Detect Epigenetic Biomarkers for Predicting Cardiovascular Disease Risk

Cardiovascular disease is a leading cause of death worldwide, yet predicting individual risk remains a persistent challenge. Traditional risk factors, while useful, do not fully capture biological changes... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.